Helsinn Healthcare S.A.: Helsinn Group Announces European Me

Helsinn Group Announces European Medicines Agency's (EMA) Acceptance for review of the Marketing Authorization Application (MAA) for Infigratinib for Patients with Cholangiocarcinoma with

Related Keywords

China , Lugano , Ticino , Switzerland , Hong Kong , Macau , Kostenloser Wertpapierhandel , Twitterand Linkedin , Paola Bonvicini , Sergio Cantoreggi , Helsinn Group , Company Marketing Authorization Application , Helsinn Group Announces European Medicinesagency , Health Authorities , Group Head Of Communication , Helsinn Group Media Contact , European Union , European Medicines Agency , Bio Pharma Inc , Health Authority , Marketing Authorization Application , Bridgebio Pharma , Helsinn Group Chief Scientific Officer , Global Head , Group Media Contact , Helsinn , Healthcare , Group , Nnounces , European , Medicines , Agency , Acceptance , Review , Marketing , Authorization , Application , Infigratinib , Patients , Cholangiocarcinoma , Fibroblast , Growth , Factor , Eceptor ,